Co-Diagnostics (NASDAQ:CODX) to join Russell 2000® and 3000® Indexes

New York City, New York, June 11, 2020 (GLOBE NEWSWIRE) -- Co-Diagnostics (NASDAQ:CODX), announced earlier this week that the molecular diagnostics company is set to join the broad-market Russell 3000® Index and Russell 2000® Index at the conclusion of the Russell US Indexes and Russell Global Indexes annual reconstitution (effective after the U.S. market opens on June 29).

Membership in the US all-cap Russell 3000® Index means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. Membership in the Russell Global Index means automatic inclusion in the appropriate large-cap, small-cap, all-cap indexes as well as the applicable style, sector and country indexes.

FTSE Russell determines membership for its Russell indexes by objective, market-capitalization rankings and style attributes. Russell US Indexes are part of FTSE Russell, a leading global index provider. FTSE Russell is wholly owned by London Stock Exchange Group.

What can we expect to happen to Co-Diagnostics shares after its inclusion in the Russell 3000®? 

In a study from a few years ago, the authors found that Russell 2000® inclusion resulted in more trading in June, after end-of-May capitalizations are calculated, and that activity is consistent with investors rebalancing and tracking stocks. The just-added stocks have more trading volume than stocks that just missed addition to an index, while the just-deleted stocks have more trading volume than stocks that stayed in the index.

Inclusion in the Indexes is expected to increase the company’s exposure among investors, especially among institutions, provide additional liquidity for the stock and broaden the shareholder base. Russell US Indexes are widely used by investment managers and institutional investors as the basis for index funds and as benchmarks for active investment strategies. The company sees being named to the Russell Indexes is an acknowledgement of the progress Co-Diagnostics has made and the strong support from the investment community.

Approximately $9 trillion in assets under management (AUM) are benchmarked to or invested in products based on the Russell US Indexes, 18% of which is to the Russell 2000® alone, underlining the importance of reconstitution to the financial markets.

For more information on the Russell 3000® Index and the Russell US Indexes reconstitution, go to the "Russell Reconstitution" section on the FTSE Russell website.

Disclosure: Co-Diagnostics Inc is a client of BDA International.

About BDA International, Inc.:

BDA International is an independent global Investor Relations firm offering a wide range of IR-related analysis, research and advisory services. In particular, we provide and are compensated for service packages that include strategic action plans and investor/market perception studies to help entities improve communication with customers and investors, and to increase their visibility. BDA International has received no direct compensation related to this release but its principles hold shares of client companies in our personal portfolios, including CODX. BDA International accepts sole responsibility for the content and distribution of the foregoing release, which does not contain any previously unpublished or non-public information. Parties interested in learning more about the relationship between BDA and CODX may do so via the contact information at the bottom of this release.

Disclaimer

The information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained in this analysis reflect our current judgment and are subject to change without notice. We do not accept any responsibility or liability for any losses, damages or costs arising from an investor’s or other person’s reliance on or use of this analysis. This analysis is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities, nor a recommendation of any security, although members of the BDA may at times hold a position in the company covered within the article. Co-Diagnostics is a client of BDA International. Past gains are not a representative of future gains. The opinions herein contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. When used herein, the words “anticipate,” “intend,” “estimate,” “believe,” “expect,” “plans,” “should,” “potential,” “forecast,” and variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A company’s actual results could differ materially from those described in any forward-looking statements contained herein. BDA is not a licensed broker, broker dealer, market maker, investment advisor, analyst or underwriter. We recommend that you use the information found herein as an initial starting point for conducting your own research in order to determine your own personal opinion of the companies discussed herein before deciding whether or not to invest. You should seek such investment, tax, financial, accounting or legal advice appropriate for your particular circumstances. Information about many publicly traded companies and other investor resources can be found at www.sec.gov. Investing in securities is speculative and carries risk.

Investor Relations Contact:

Mushtaq Dost                                                                      

BDA International    

www.bda-ir.com

[email protected]